Skip to main content

Table 3 Adverse events (AE) (≥ grade III)

From: Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial

AE (≥ grade III), n

Whole cohort

(n = 38)

GEM arm (n = 20)

GEM + SBRT arm

(n = 18)

P

Neutropenia

3

2

1

0.612

Thrombocytopenia

1

0

1

0.285

Fatigue

1

0

1

0.285

Anorexia

3

1

2

0.485

Anaemia

0

0

0

-

Nausea or vomitting

5

3

2

0.723

Diarrhea

0

0

0

-

Liver dysfunction

3

2

1

0.612